NASDAQ: IMNN
Imunon Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their IMNN stock forecasts and price targets.

Forecast return on equity

Is IMNN forecast to generate an efficient return?

Company
-212.92%
Industry
250.21%
Market
227.93%
IMNN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is IMNN forecast to generate an efficient return on assets?

Company
-96.69%
Industry
89.99%
IMNN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

IMNN earnings per share forecast

What is IMNN's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$5.33
Avg 2 year Forecast
-$3.80
Avg 3 year Forecast
-$3.69

IMNN revenue forecast

What is IMNN's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

IMNN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
IMNN$3.75N/AN/A
PHIO$1.07$14.00+1,208.41%Buy
CLRB$2.68N/AN/A
SNSE$8.86$30.00+238.60%Buy
LGVN$0.56$3.00+437.63%Strong Buy

Imunon Stock Forecast FAQ

What is IMNN's earnings growth forecast for 2025-2027?

(NASDAQ: IMNN) Imunon's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.17%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.43%.

Imunon's earnings in 2025 is -$14,329,403.On average, 6 Wall Street analysts forecast IMNN's earnings for 2025 to be -$16,363,452, with the lowest IMNN earnings forecast at -$23,048,533, and the highest IMNN earnings forecast at -$8,994,602. On average, 5 Wall Street analysts forecast IMNN's earnings for 2026 to be -$11,659,055, with the lowest IMNN earnings forecast at -$14,128,848, and the highest IMNN earnings forecast at -$8,865,647.

In 2027, IMNN is forecast to generate -$11,315,176 in earnings, with the lowest earnings forecast at -$14,521,546 and the highest earnings forecast at -$7,737,292.

If you're new to stock investing, here's how to buy Imunon stock.

What is IMNN's revenue growth forecast for 2025-2027?

(NASDAQ: IMNN) Imunon's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 99.6%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.68%.

Imunon's revenue in 2025 is $0.On average, 6 Wall Street analysts forecast IMNN's revenue for 2025 to be $0, with the lowest IMNN revenue forecast at $0, and the highest IMNN revenue forecast at $0. On average, 5 Wall Street analysts forecast IMNN's revenue for 2026 to be $0, with the lowest IMNN revenue forecast at $0, and the highest IMNN revenue forecast at $0.

In 2027, IMNN is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is IMNN's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: IMNN) forecast ROA is -96.69%, which is lower than the forecast US Biotechnology industry average of 89.99%.

What is IMNN's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: IMNN) Imunon's current Earnings Per Share (EPS) is -$11.01. On average, analysts forecast that IMNN's EPS will be -$5.33 for 2025, with the lowest EPS forecast at -$7.51, and the highest EPS forecast at -$2.93. On average, analysts forecast that IMNN's EPS will be -$3.80 for 2026, with the lowest EPS forecast at -$4.60, and the highest EPS forecast at -$2.89. In 2027, IMNN's EPS is forecast to hit -$3.69 (min: -$4.73, max: -$2.52).

What is IMNN's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: IMNN) forecast ROE is -212.92%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.